SCHEMBL6316115

SCHEMBL6316115

CCCCCCCNC(=O)c1c(-c2ccc(Cl)o2)noc1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.53
CA1 P00915 1/20 0.53
CA4 P22748 1/20 0.53
CA7 P43166 1/20 0.53
PTGS1 P23219 3/20 0.43
HPGD P15428 1/20 0.41
NAAA Q02083 4/20 0.41
CNR1 P21554 1/20 0.41
GAA P10253 1/20 0.40
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316009 1.00 CA2 (0.53) CA2CA1CA4CA7PTGS1
SCHEMBL6315617 1.00 CA2 (0.53) CA2CA1CA4CA7PTGS1
SCHEMBL6321782 0.99 CA1 (0.54) CA2CA1CA4CA7PTGS1
SCHEMBL6322776 0.96 CA1 (0.55) CA2CA1CA4CA7PTGS1
SCHEMBL6324189 0.90 CA1 (0.50) CA2CA1CA4CA7PTGS1
SCHEMBL6317241 0.88 HPGD (0.44) CA2CA1CA4CA7HPGD
SCHEMBL6324777 0.88 HPGD (0.44) CA2CA1CA4CA7HPGD
SCHEMBL6315590 0.88 HPGD (0.44) CA2CA1CA4CA7HPGD
SCHEMBL6316084 0.87 HPGD (0.45) CA2CA1CA4CA7HPGD
SCHEMBL6317803 0.86 CA1 (0.53) CA2CA1CA4CA7PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 CA2 2764/4885CA1 2406/4885CA4 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.